We investigated the bio-distributions of [125 I]Spiro-I formulated in sterically stabilized liposomes （SSL） or targeted liposomes （SSTL） in mice,especially their brain uptake.The [125 I]Spiro-I liposomes were prepared by film-ultrasound dispersion method.Cereport （RMP-7） was covalently conjugated with DSPE-PEG,which was attached to the surface of SSL to form SSTL.The encapsulation efficiencies （ee%） of [125 I]Spiro-I-SSL and [125 I]Spiro-I-SSTL were 97.47%±4.01% and 93.02%±2.98%,respectively.The average particle sizes were （66.47±0.76） nm and （71.40±0.45） nm,respectively.After intravenous administration,[125 I]Spiro-I was quickly eliminated from blood.SSL could prolong the retention time of [125 I]Spiro-I in blood and SSTL improved its brain uptake.The AUC of [125 I]Spiro-I-SSTL in brain was increased by 1.52 times as compared to [125 I]Spiro-I,indicating that SSTL could be used for the formulation of [125 I]Spiro-I for the imaging of central nervous system （CNS）.
Oleanolic acid-loaded solid lipid nanoparticles（OA-SLNs）were prepared by using an improved emulsion-solvent evaporation method.The size,zeta potential,encapsulation efficiency,and loading efficiency of OA-SLNs were（104.5±11.7）nm, （-25.5±1.8）mV,（94.2±3.9）%,and（4.71±0.15）%,respectively.The morphology was illustrated by TEM as sphere stuffed particles.The XRD and DSC spectra confirmed that the OA molecules were dispersed uniformly into SLN matrixes.The results of in vitro release test suggested that OA was released slowly at a rate of 4.88%per hour from SLN preparation,which was consistent with the Zero-order Released Model.In addition,OA-SLNs were stable in artificial gastric juice and artificial intestinal juice.Together,our results provided new data for the potential application of OA-SLNs in oral administration.
